Egyptian Hypertrophic Cardiomyopathy Program

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-01

Study Completion Date

2030-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Egyptian HCM program aims at defining incidence, severity, phenotype, genotype and determinants of the disease in Egypt, and providing state-of-the-art treatment strategies including medical, surgical and interventional procedures which are patient- and disease-specific.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Presentation, Patterns of Myocardial Damage, and Clinical Course of Viral Myocarditis

NCT04312490

Myocarditis Viral

COMPLETED NA

Early Results Of Coronary Artery Reconstruction For Extensive Coronary Disease

NCT05891392

Coronary Reconstruction

UNKNOWN

Observational Study for Patients With Hypertrophic Cardiomyopathy

NCT04851652

HCM - Hypertrophic Cardiomyopathy

RECRUITING

Assiut University Registry for ACS Patients During COVID-19 Pandemic

NCT04691609

ACS-COVID-19-Assiut

UNKNOWN

A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)

NCT05981092

Cardiomyopathy, Dilated Bcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM)

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project aims to:

* Define incidence, severity, phenotype, genotype and determinants of the disease in Egypt.
* Characterise the phenotype and genotype of several large cohorts with inherited muscle disease and their relatives.
* Provide state-of-the-art treatment strategies including medical, surgical and interventional procedures which are patient- and disease-specific.
* Study the basic mechanisms responsible for the different phenotypes at a molecular and cellular level including genotype-phenotype correlation.
* Provide a special focus for studying patients who are genotype positive and phenotype negative which we believe could yield critical data regarding the evolution of the disease.
* Develop sophisticated laboratory studies for single cell electrophysiology and immunocytochemistry and others focusing on the explanted human material from the surgical program.
* Define the role of microvascular coronary artery in the development and progression of the disease.
* Training Egyptian cardiologists, cardiac surgeons and scientists on state-of-the-art diagnosis and management of heart muscle disease including the latest developments in imaging, novel surgical techniques, coronary physiology, next generation sequencing, bioinformatics and cellular electrophysiology.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertrophic Cardiomyopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All patients diagnosed with hypertrophic cardiomyopathy (index patients) who are willing and consented to participate in the registry.
* All family members of index patients who are willing and consented to participate in the registry.